A study to evaluate the safety and efficacy of Universal Donor NK Cells in combination with Gemcitabine and Docetaxel in patients with relapsed/refractory pediatric bone and soft tissue sarcoma.
Study Details
Internal Title:
Cell Therapy TiNKS Trial MCC21704
PCH IRB Number:
IRB-REL-25-185
Clinical Trials Government Identifier:
NCT05634369
Diagnoses & Treatments:
sarcoma, cancer, bone cancer, soft tissue cancer, relapsed sarcoma, refractory sarcoma, NK cell, cellular therapy
Study Type:
Clinical Trial
Eligibility:
2 to 40 years of age, diagnosis of relapsed/refractory sarcoma, at least one and no more than four total lines of cytotoxic systemic treatments
Enrollment Status:
Open
Phase:
I/II